BioNTech Investor Day Presentation Deck

Developing 3 autologous cell therapy platforms and addressing novel targets Chimeric antigen receptor (CAR)¹ aCLDN6 scFv CD8 hinge 4-1BB CD32 CARVac Autologous engineered cell therapy to address extra-cellular targets RNA-LPX vaccine Lead program: BNT211 CARVac targeting CLDN6 Reinhard K, et al. Science 2020; 367:446-453 NEO-STIM Individualized ex-vivo T-cell therapy targeting neoantigens Lead program: BNT221 across multiple solid tumors ● ● T-cell receptor (TCR) B εδ Ty Engineered cell therapy to address both intra- and extra-cellular targets Individualized TCR-T in development Cell therapies Programs: KRAS, PRAME TCRs BIONTECH 132

View entire presentation